Marinus Pharmaceuticals, Inc. (MRNS): Price and Financial Metrics

Marinus Pharmaceuticals, Inc. (MRNS)

Today's Latest Price: $14.73 USD

0.10 (-0.67%)

Updated Dec 3 12:20pm

Add MRNS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

MRNS Stock Price Chart Interactive Chart >

Price chart for MRNS

MRNS Price/Volume Stats

Current price $14.73 52-week high $17.14
Prev. close $14.83 52-week low $4.16
Day low $14.45 Volume 250,529
Day high $15.10 Avg. volume 618,075
50-day MA $14.00 Dividend yield N/A
200-day MA $10.05 Market Cap 450.65M

Marinus Pharmaceuticals, Inc. (MRNS) Company Bio

Marinus Pharmaceuticals is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The company was founded in 2003 and is based in Radnor, Pennsylvania.

MRNS Latest News Stream

Event/Time News Detail
Loading, please wait...

MRNS Latest Social Stream

Loading social stream, please wait...

View Full MRNS Social Stream

Latest MRNS News From Around the Web

Below are the latest news stories about Marinus Pharmaceuticals Inc that investors may wish to consider to help them evaluate MRNS as an investment opportunity.

Marinus closing in on launch of pivotal study of ganaxolone in life-threatening type of epilepsy

Marinus Pharmaceuticals (MRNS) announces that it has satisfied the FDA's questions regarding the protocol of a Phase 3 clinical trial, RAISE, evaluating intravenous ((IV)) ganaxolone in patients with an extremely severe and life-threatening type of epilepsy called refractory status epilepticus ((RSE)) characterized by seizures that last five minutes or longer...

Seeking Alpha | September 24, 2020

Marinus Provides Corporate Update on Phase 3 RAISE Trial in Status Epilepticus (SE)

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #BARDA--Marinus Pharmaceuticals has satisfied the FDA's protocol-specific questions for its Phase 3 trial in RSE and announces VPs, Clinical Development.

Business Wire | September 24, 2020

Arbutus Reports Positive Hepatitis B Data, And Other News: The Good, Bad And Ugly Of Biopharma

Arbutus reports positive data for AB-729 for chronic hepatitis B Arbutus Biopharma Corporation (ABUS) announced continued positive data from a continuing Phase 1a/1b clinical trial of AB-729. The new data showed that a single subcutaneous injection of 90 mg of AB-729 leads to a mean HBsAg decline of 1.23 log10...

Avisol Capital Partners on Seeking Alpha | September 22, 2020

The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...

Benzinga | September 17, 2020

The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than...

Benzinga | September 16, 2020

Read More 'MRNS' Stories Here

MRNS Price Returns

1-mo 7.52%
3-mo 100.14%
6-mo 34.15%
1-year 234.77%
3-year -47.54%
5-year -41.64%
YTD 70.49%
2019 -24.74%
2018 -64.83%
2017 707.92%
2016 -86.78%
2015 -27.72%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8829 seconds.